The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK. The NDA measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales. The NDA collects and analyses data for use by a range of stakeholders to drive changes and improvements in the quality of services and health outcomes for people with diabetes. This report details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for the 2018-19 audit. The audit collected data during May and June 2019, for the period 01 January 2018 to 31 March 2019. This report follows the NDA short report publication in December 2019, which provided the top level findings for the 2018-19 audit, along with local level data made available to services in a timely manner that can help drive improvements in the quality of diabetes care locally. A new method of collecting structured education attendance data was trialled for 2018-19. In addition to extracting education data from GP practice systems, structured education providers could submit data directly via the Clinical Audit Platform (CAP). Around 20 providers submitted, however only a small proportion of records were submitted with the required data. This exercise has shown the potential value of this additional collection and improvements to the process are being developed to improve future collections. Included within this publication is the National Diabetes Insulin Pump Audit interactive reporting and supporting information. It provides information on people with Type 1 diabetes on an insulin pump at National, LHB, and Specialist Diabetes Service level for the 2018-19 audit period. Note: An error was identified in the original release of the National Diabetes Insulin Pump Audit 2018-19, Interactive Report for Specialist Services in England. The number of people with Type 1 diabetes in the 'HbA1c values' section was overstated and showed the total number of people with any type of diabetes seen at the service. This has been corrected and replaced with a new version of the report on 23 December 2020.

The National Pregnancy in Diabetes Audit (NPID) is a workstream of the National Diabetes Audit (NDA) and is managed by NHS Digital under an agreement with the Healthcare Quality Improvement Partnership (HQIP) on behalf of NHS England and the Welsh Government. The NDA is delivered by NHS Digital, in partnership with Diabetes UK. The audit is a measurement system to support improvement in the quality of care for women with diabetes who are pregnant or planning pregnancy and seeks to address three key questions: Were women with diabetes adequately prepared for pregnancy? Were adverse maternal outcomes during pregnancy minimised? Were adverse fetal/infant outcomes minimised? NPID is the largest continuous audit of pregnancy in women with diabetes in the world (more than 4,500 pregnancies in 2020). We now have seven years of data which has allowed a depth of analysis not previously possible.

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. This is the Type 1 Diabetes report. It details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for people with type 1 diabetes. The 2019-20 audit covers the period 01 January 2019 to 31 March 2020. This is the first NDA report dedicated to people with type 1 diabetes. A new diagnosis validation process, which considers medication as well as recorded diagnosis, has been introduced to try to ensure that only people with true type 1 diabetes are included (see appendix). Results are to be taken in the context of low data submission from specialist services, possibly hampered due to COVID-19.

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK. The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to: Assess local practice against NICE guidelines. Compare their care, and care outcomes, with similar services and organisations. Identify gaps or shortfalls that are priorities for improvement. Identify and share best practice and provide a comprehensive national picture of diabetes care and outcomes in England and Wales. This data release includes the care process and treatment target measurements for 2020-21 (1st January 2020 – 31st March 2021). Data were collected during May and June 2021. The national report, scheduled for 2022, will contain commentary on the audit findings and recommendations. We will communicate to users when the publication date for this report has been finalised. Note: An issue was identified with the Wales data release whereby structured education offered data was underreported. This has now been corrected in the version of the file available on this webpage.

North America Sulfonylureas Market size was valued at USD 3.1 Billion in 2024 and is Projected to reach USD 3.9 Billion by 2032, growing at a CAGR of 1.9% from 2025 to 2032.

Key Market Drivers:

Increasing Prevalence of Type 2 Diabetes: According to the Centers for Disease Control and Prevention's (CDC) National Diabetes Statistics Report, approximately 37.3 million Americans (11.3% of the population) had diabetes in 2020, with Type 2 diabetes accounting for 90-95% of cases. This high incidence increases demand for sulfonylureas, which are still one of the most commonly recommended second-line treatments for Type 2 diabetes.

Cost-Effectiveness in Relation to Newer Medications: Sulfonylureas are far more cheap than modern diabetes treatments. According to a research published in the Journal of the American Medical Association (JAMA), the average monthly cost of sulfonylureas was $4-11, whereas newer GLP-1 receptor agonists cost $350-500.

The information available from this webpage comes from the National Diabetes Inpatient Audit. The National Diabetes Inpatient Audit is a snapshot audit of diabetes inpatient care. During September 2019, hospitals across England collected data on the characteristics of the hospital, including participation, staffing levels and care improvement initiatives. Wales did not participate in NaDIA 2019. Making clinical audit data transparent In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme. What information is being made available? National Diabetes Inpatient Audit data for 2019 is available at hospital site level for: * Audit participation and data completeness for the key fields * Measures about the process of care given to patients * Information about care outcomes and treatment. These data do not list individual patient information nor do they contain any patient identifiable data. Using and interpreting the data Data from the National Diabetes Inpatient Audit should not be looked at in isolation when assessing standards of care. Accessing the data The data are being made available on the data.gov website. Each year a data file from the National Diabetes Inpatient Audit will be made available in CSV format. Hospitals are identified by name and their national code. What period does the data cover? This report covers hospital characteristics during September 2019. The audit report was published on 13 November 2020. Historic data is available for previous audit years (2010-2013, 2015-2017) where survey questions were comparable.

NaDIA-Harms is a mandatory year-round collection of four harms that can occur to diabetic inpatients in Acute hospitals in England. The objective of NaDIA Harms is to help reduce the rates of serious inpatient harms by collecting and providing case mix adjusted benchmarked feedback to hospital trusts to inform quality improvement work.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

What information is being made available?

National Diabetes Inpatient Audit – Harms data for 2019 is available at national level for:

• Audit participation
• The number of harms
• Patient profiles

and at NHS trust level for:

• Audit participation

These data do not list individual patient information nor do they contain any patient identifiable data.

Using and interpreting the data

Data from the National Diabetes Inpatient Audit – Harms should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. Each year a data file from the National Diabetes Inpatient Audit - Harms will be made available in CSV format.

What period does the data cover?

The report covers impatient harms between May 2018 and October 2019. The audit report was published on 13 November 2020.

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against the National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This NICE guidance is based on evidence that regular systematic review of people with diabetes and achievement of glucose, blood pressure and cardiovascular risk standards maintains health and reduces long term complications.

The excel file contains unit, regional and national level data obtained from the National Paediatric Diabetes Audit 2018-2019. Specifically, it includes information on patient characteristics, completion of health checks and outcomes achieved (as recommended by the National Institute for Clinical Excellence) for infants, children and young people with type 1 diabetes, under the age of 25, who attended paediatric diabetes units in England and Wales between 1 April 2018 and the 31 March 2019. Data are included for the seven key health checks: • Glycated Haemoglobin A1c (HbA1c) • Body Mass Index (BMI) • Thyroid • Blood pressure • Urinary albumin • Foot examination • Eye screening. Data on other health checks include: • Psychological assessment • Offering of immunisation against influenza • Advice about managing diabetes (‘sick-day rules’) • Using (or trained to use) blood ketone testing strips and a meter • Cholesterol • Additional dietetic support Data are included for health checks at diagnosis • Screening for autoimmune disease (coeliac and thyroid disease) • Provision of Level 3 carbohydrate-counting education Data on outcomes of care include: • HbA1c target measurements • Small vessel (microvascular) disease • Large vessel (macrovascular) disease • Autoimmune disease (coeliac and thyroid disease) The data were first published in 2020 alongside the National Paediatric Diabetes Audit Report 2018-2019 Data suppressed due to small numbers (

This is the quarterly release of data from the National Diabetes Audit (NDA). It is the mid-year data release for the third extraction of NDA 2019-20 data. It shows progress to date covering the period 1 January to 31 December 2019. The first data extraction was withdrawn this year so that the delayed biannual SNOMED code release could be incorporated into the NDA 2019-20 extract. Quarterly data release summary: • First data extraction releases will cover the six month period 1 January to 30 June; • Second data extraction releases will cover the nine month period 1 January to 30 September; • Third data extraction releases will cover the twelve month period 1 January to 31 December; • The full audit year report will continue to cover the fifteen month period 1 January to 31 March the following year. This quarterly release of data should not be used to assess performance against the annual processes as it does not include the full fifteen month audit period. It shows partial year progress against care processes and treatment targets. It also provides the latest position on structured education. It therefore can be used as an operational planning tool to assess progress to date. Care process completion is expected to increase before the end of the year. Treatment target achievement is calculated from the latest reading for each target, so achievement may go down or up. The recording of structured education may also increase. The complete audit year performance, covering 1 January 2019 to 31 March 2020, will be made available later in the year. The data published here is for English GP practices only. The complete audit year publications will include Welsh GP practices, as well as participating specialist diabetes services in England. The data has not been through the full data assurance process that is carried out on the annual data, but is a provisional reflection of progress over this partial year period.

National Paediatric Diabetes Audit 2019 - 2020 The excel file contains unit, regional and national level data obtained from the National Paediatric Diabetes Audit 2019-2020. Specifically, it includes information on patient characteristics, completion of health checks and outcomes achieved (as recommended by the National Institute for Clinical Excellence) for infants, children and young people with type 1 diabetes, under the age of 25, who attended paediatric diabetes units in England and Wales between 1 April 2019 and the 31 March 2020. Data are included for the seven key health checks: • Glycated Haemoglobin A1c (HbA1c) • Body Mass Index (BMI) • Thyroid • Blood pressure • Urinary albumin • Foot examination • Eye screening. Data on other health checks include: • Psychological assessment • Offering of immunisation against influenza • Advice about managing diabetes (‘sick-day rules’) • Using (or trained to use) blood ketone testing strips and a meter • Cholesterol • Additional dietetic support Data are included for health checks at diagnosis • Screening for autoimmune disease (coeliac and thyroid disease) • Provision of Level 3 carbohydrate-counting education Data on outcomes of care include: • HbA1c target measurements • Small vessel (microvascular) disease • Large vessel (macrovascular) disease • Autoimmune disease (coeliac and thyroid disease) The data were first published in 2021 alongside the National Paediatric Diabetes Audit Report 2019-2020 Data suppressed due to small numbers (

The NHS Diabetes Prevention Programme (NHS DPP) is a joint commitment from NHS England, Public Health England and Diabetes UK to deliver, at scale, evidence based behavioural interventions that can prevent or delay the onset of Type 2 diabetes in adults identified as having non-diabetic hyperglycaemia. The DPP report uses data collected alongside the National Diabetes Audit (NDA) for the period January 2019 to March 2020 and data from providers of the Diabetes Prevention Programme relating to referrals up to March 2020 inclusive. This report is for England only.

Het Excel-bestand bevat gegevens op eenheids-, regionaal en nationaal niveau die zijn verkregen uit de Nationale Kinderdiabetes Audit 2020-2021. Het bevat met name informatie over patiëntkenmerken, de voltooiing van gezondheidscontroles en bereikte resultaten (zoals aanbevolen door het National Institute for Clinical Excellence) voor zuigelingen, kinderen en jongeren met type 1-diabetes, jonger dan 25 jaar, die tussen 1 april 2020 en 31 maart 2021 pediatrische diabetesafdelingen in Engeland en Wales hebben bezocht. Er zijn gegevens opgenomen voor de zeven belangrijkste gezondheidscontroles: • Geglyceerd hemoglobine A1c (HbA1c) • Lichaamsmassa-index (BMI) • Schildklier • Bloeddruk • Urine-albumine • Voetonderzoek • Oogonderzoek.

Gegevens over andere gezondheidscontroles zijn onder meer:

• Psychologische beoordeling • Aanbieden van immunisatie tegen influenza • Advies over de behandeling van diabetes (“ziektedagregels”) • Gebruik van (of getraind in het gebruik van) bloedketonteststrips en een meter • Cholesterol • Extra dieetondersteuning Gegevens zijn opgenomen voor gezondheidscontroles bij diagnose • Screening op auto-immuunziekte (coeliakie en schildklierziekte) • Verlening van opleiding voor het tellen van koolhydraten op niveau 3 Gegevens over de resultaten van de zorg omvatten: • HbA1c doelmetingen • Ziekte van kleine vaten (microvasculaire ziekte) • Groot vat (macrovasculaire) ziekte • Auto-immuunziekte (coeliakie en schildklierziekte)

De gegevens werden voor het eerst gepubliceerd in 2022 naast het National Paediatric Diabetes Audit Report 2020-2021 Data suppressed because small numbers (<5).

Voor meer informatie en details over de audit wordt verwezen naar:

• Jaarverslagen van de nationale controle van pediatrische diabetes: https://www.rcpch.ac.uk/resources/npda-jaarverslagen

• NPDA-resultaten online: http://npda-results.rcpch.ac.uk/default.aspx

• De website van RCPCH: https://www.rcpch.ac.uk/npda

analyze the national health and nutrition examination survey (nhanes) with r nhanes is this fascinating survey where doctors and dentists accompany survey interviewers in a little mobile medical center that drives around the country. while the survey folks are interviewing people, the medical professionals administer laboratory tests and conduct a real doctor's examination. the b lood work and medical exam allow researchers like you and me to answer tough questions like, "how many people have diabetes but don't know they have diabetes?" conducting the lab tests and the physical isn't cheap, so a new nhanes data set becomes available once every two years and only includes about twelve thousand respondents. since the number of respondents is so small, analysts often pool multiple years of data together. the replication scripts below give a few different examples of how multiple years of data can be pooled with r. the survey gets conducted by the centers for disease control and prevention (cdc), and generalizes to the united states non-institutional, non-active duty military population. most of the data tables produced by the cdc include only a small number of variables, so importation with the foreign package's read.xport function is pretty straightforward. but that makes merging the appropriate data sets trickier, since it might not be clear what to pull for which variables. for every analysis, start with the table with 'demo' in the name -- this file includes basic demographics, weighting, and complex sample survey design variables. since it's quick to download the files directly from the cdc's ftp site, there's no massive ftp download automation script. this new github repository co ntains five scripts: 2009-2010 interview only - download and analyze.R download, import, save the demographics and health insurance files onto your local computer load both files, limit them to the variables needed for the analysis, merge them together perform a few example variable recodes create the complex sample survey object, using the interview weights run a series of pretty generic analyses on the health insurance ques tions 2009-2010 interview plus laboratory - download and analyze.R download, import, save the demographics and cholesterol files onto your local computer load both files, limit them to the variables needed for the analysis, merge them together perform a few example variable recodes create the complex sample survey object, using the mobile examination component (mec) weights perform a direct-method age-adjustment and matc h figure 1 of this cdc cholesterol brief replicate 2005-2008 pooled cdc oral examination figure.R download, import, save, pool, recode, create a survey object, run some basic analyses replicate figure 3 from this cdc oral health databrief - the whole barplot replicate cdc publications.R download, import, save, pool, merge, and recode the demographics file plus cholesterol laboratory, blood pressure questionnaire, and blood pressure laboratory files match the cdc's example sas and sudaan syntax file's output for descriptive means match the cdc's example sas and sudaan synta x file's output for descriptive proportions match the cdc's example sas and sudaan syntax file's output for descriptive percentiles replicate human exposure to chemicals report.R (user-contributed) download, import, save, pool, merge, and recode the demographics file plus urinary bisphenol a (bpa) laboratory files log-transform some of the columns to calculate the geometric means and quantiles match the 2007-2008 statistics shown on pdf page 21 of the cdc's fourth edition of the report click here to view these five scripts for more detail about the national health and nutrition examination survey (nhanes), visit: the cdc's nhanes homepage the national cancer institute's page of nhanes web tutorials notes: nhanes includes interview-only weights and interview + mobile examination component (mec) weights. if you o nly use questions from the basic interview in your analysis, use the interview-only weights (the sample size is a bit larger). i haven't really figured out a use for the interview-only weights -- nhanes draws most of its power from the combination of the interview and the mobile examination component variables. if you're only using variables from the interview, see if you can use a data set with a larger sample size like the current population (cps), national health interview survey (nhis), or medical expenditure panel survey (meps) instead. confidential to sas, spss, stata, sudaan users: why are you still riding around on a donkey after we've invented the internal combustion engine? time to transition to r. :D

The National Diabetes Audit (NDA) and the National Paediatric Diabetes Audit (NPDA) provide a comprehensive view of diabetes care in England and Wales. They measure the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This is the second Young People with Type 2 Diabetes report (1). It aims to document the number of people with type 2 diabetes up to the age of 40 years, their patient characteristics and the diabetes care they receive. This is important because adverse diabetes and cardiovascular outcomes are more common in people who develop type 2 diabetes at an earlier age and it is thought the numbers of affected individuals are increasing (2,3).

The National Diabetes Foot Care Audit (NDFA) is a continuous audit of diabetic foot disease in England and Wales. The audit enables all diabetes foot care services to measure their performance against NICE clinical guidelines and peer units, and to monitor adverse outcomes for people with diabetes who develop diabetic foot disease. All organisations which provide a diabetic foot ulcer treatment service are eligible for inclusion in the audit. The audit reports on the following: Structures: are the nationally recommended care structures in place for the management of diabetic foot disease? Processes: does the treatment of active diabetic foot disease comply with nationally recommended guidance? Outcomes: are the outcomes of diabetic foot disease optimised? The NDFA is part of the National Diabetes Audit (NDA) portfolio within the National Clinical Audit and Patient Outcomes Programme (NCAPOP), commissioned by the Healthcare Quality Improvement Partnership (HQIP) As well as a national report, which provides information about foot care across England and Wales, separate local reports are also available. The comparative local reports show data at service (specialist foot care teams), provider (Trust/Local Health Board), commissioner (Clinical Commissioning Group) and network (Strategic Clinical Network) level. 8 January 2020: text in glossary section on page 91 for questions 5 and 6 updated to correctly match the questions in the 2018 NDFA Provider Survey.

The Adolescent and Young Adult Type 1 Diabetes Audit (AYA; previously referred to as the National Diabetes Transition Audit, NDTA) links datasets from the adult and paediatric national diabetes audits. The AYA has been designed to audit care provision during the period when young people with diabetes move from paediatric to adult based clinical care. The audit covers the period 01 January 2017 to 31 March 2021 and the cohort consists of people with type 1 diabetes aged between 15 and 25 years old during the AYA period. The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards*,**. The National Paediatric Diabetes Audit (NPDA) was established to compare the care and outcomes of all children and young people with diabetes receiving care from Paediatric Diabetes Units (PDUs) in England and Wales. At the time of producing this report the Welsh NPDA data was not available to NHS Digital. Therefore, to ensure timescales for publication of this population level report were met, only England data is included (94.7% of the combined data***). Welsh NPDA data has since become available meaning Welsh data is included in the national and locality level dashboard accompanying this report. Consequently, the combined England and Wales national results in the dashboard may be slightly different to the England national results in this report. -* NICE Clinical Guidelines – NG17: Type 1 diabetes in adults: diagnosis and management http://www.nice.org.uk/guidance/ng17 ** NICE – Diabetes in Adults Quality Standard http://guidance.nice.org.uk/QS6. *** ONS 2020 mid-year population estimates for England and Wales.

The National Pregnancy in Diabetes Audit (NPID) is a workstream of the National Diabetes Audit (NDA) and is managed by NHS England (formally NHS Digital) under an agreement with the Healthcare Quality Improvement Partnership (HQIP). The NDA is delivered by NHS England, in partnership with Diabetes UK. The audit has been running since 2014. This is the seventh National Pregnancy in Diabetes (NPID) audit report on pregnancy outcomes in women with pre-existing diabetes in pregnancy in England and Wales. This State of the Nation overview details the findings and recommendations relating to the demographics, treatment and pregnancy outcomes of mothers with type 1 and early-onset type 2 diabetes. It covers the period 01 January 2021 to 31 December 2022.